Immunotherapies for Ischemic Stroke Patients: Current Status and Future Directions
It is evident that reducing neuroinflammation is an important component of reducing brain tissue loss and functional impairments after stroke. A combination of therapies may be more effective for stroke-affected patients. This could include reducing neuroinflammation through immune therapies, in combination with some pharmaceuticals specific to the patient's needs. Furthermore, sex differences are highly prevalent in ischemic stroke outcomes. These differences can inform us of the best sex-specific interventions, treatments, or techniques that should be used in healthcare to ensure lower mortality rates and higher quality of life for all. Therapeutic development for ischemic stroke is needed, and this review highlights that targeting the immune system could lead to better outcomes for patients.
Authors
- Lauren Hurley (ORCID: https://orcid.org/0009-0006-0361-3090)
- Kasey Pull
- Riley McCabe
- Nafisa M. Jadavji
Institutions
- Southern Illinois University Carbondale (US)
- Midwestern University (US)
- University of Arizona (US)
- Carleton University (CA)
Publication Details
- Journal
- Medical Sciences
- Published
- 2026-02-25
- DOI
- https://doi.org/10.3390/medsci14010111
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00